STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 99 filers reported holding STOKE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.42 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12 | -62.5% | 2,968 | 0.0% | 0.00% | – |
| Q2 2023 | $32 | +14.3% | 2,968 | -12.4% | 0.00% | – |
| Q1 2023 | $28 | +33.3% | 3,387 | +46.7% | 0.00% | – |
| Q4 2022 | $21 | -99.9% | 2,309 | +26.0% | 0.00% | – |
| Q3 2022 | $24,000 | +14.3% | 1,833 | +18.0% | 0.00% | – |
| Q2 2022 | $21,000 | -22.2% | 1,553 | +26.5% | 0.00% | – |
| Q1 2022 | $27,000 | +12.5% | 1,228 | +25.3% | 0.00% | – |
| Q4 2021 | $24,000 | +26.3% | 980 | +31.9% | 0.00% | – |
| Q3 2021 | $19,000 | -24.0% | 743 | 0.0% | 0.00% | – |
| Q2 2021 | $25,000 | -13.8% | 743 | 0.0% | 0.00% | – |
| Q1 2021 | $29,000 | -37.0% | 743 | 0.0% | 0.00% | – |
| Q4 2020 | $46,000 | +84.0% | 743 | 0.0% | 0.00% | – |
| Q3 2020 | $25,000 | +38.9% | 743 | 0.0% | 0.00% | – |
| Q2 2020 | $18,000 | +5.9% | 743 | 0.0% | 0.00% | – |
| Q1 2020 | $17,000 | -19.0% | 743 | 0.0% | 0.00% | – |
| Q4 2019 | $21,000 | – | 743 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 296,822 | $7,551,000 | 1.86% |
| RTW INVESTMENTS, LP | 3,644,248 | $92,710,000 | 1.40% |
| Cormorant Asset Management, LP | 1,278,276 | $32,519,000 | 1.32% |
| Redmile Group, LLC | 2,381,958 | $60,597,000 | 1.06% |
| HighVista Strategies LLC | 47,594 | $1,211,000 | 0.80% |
| Birchview Capital, LP | 15,000 | $382,000 | 0.26% |
| GILDER GAGNON HOWE & CO LLC | 1,123,355 | $28,578,000 | 0.15% |
| Artal Group S.A. | 250,000 | $6,360,000 | 0.14% |
| Tekla Capital Management LLC | 99,263 | $2,525,000 | 0.08% |
| Casdin Capital, LLC | 120,000 | $3,053,000 | 0.08% |